Rapalog Pharmacology (RAP PAC) Study

Study Details

Study Description

Brief Summary

The objective of RAP PAC is to identify safe and effective weekly dose(s) for the mTOR inhibitors sirolimus and everolimus that intervene on the underlying fundamental biology of aging. Participants who are 55-80 years old that are free of overt chronic diseases will be assigned to either 6 weeks of sirolimus or everolimus (5 mg, 10 mg, or 15 mg once per week). The investigators will complete the everolimus arm first and then subsequently complete the sirolimus arm of the study. Total time on study would be up to 17 weeks to complete baseline and follow up visits.

Condition or Disease	Intervention/Treatment	Phase
Aging	Drug: Sirolimus Drug: Everolimus	Phase 1

Detailed Description

The mTOR inhibitor rapamycin and rapamycin analogs (rapalogs) extend healthspan and/or lifespan in multiple model systems. However, the risk of adverse events and dose limiting toxicities in humans have thus far precluded the long-term prophylactic use of mTOR inhibitors as a therapy for aging and age-related diseases. The pharmacokinetics and pharmacodynamics (PK/PD) data for mTOR inhibitors in older adults is currently unknown and has prevented the identification of a safe dosage that could maximize health-span extension and minimize adverse effects.

RAP PAC will identify a recommended phase 2 trial dose for sirolimus and everolimus in older men and women by performing a phase 1, dose finding study that evaluates PK/PD, safety and tolerability, and mTOR signaling using conventional as well as novel approaches. Overall, the investigators will pair comprehensive molecular and pharmacologic approaches to evaluate PK/PD in humans and identify dosing regimens that safely inhibit mTOR complex 1 (mTORC1) to intervene in the biology of aging.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

72 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

The Bayesian Optimal Interval Design (BOIN) will be used to perform a phase I, dose finding trial in healthy older men and women (55-80yrs) for the mTOR inhibitors sirolimus and everolimus. Middle-aged to older adults will be treated with either sirolimus or everolimus for 6 weeks. All participants will take one capsule weekly. This dose escalation trial will begin with two cohorts, each consisting of 3 male and 3 female participants. The first two cohorts will take a weekly 5mg dose of sirolimus or a weekly 5mg dose of everolimus. The first arm of the study will be with everolimus. The second arm of the study will be with sirolimus. The dose can be escalated/de-escalated from the current dose based on the rate of dose limited toxicity (DLT) at the end of the 6-week intervention for each cohort. The 15mg dose will be the highest dose possible in this trial.The Bayesian Optimal Interval Design (BOIN) will be used to perform a phase I, dose finding trial in healthy older men and women (55-80yrs) for the mTOR inhibitors sirolimus and everolimus. Middle-aged to older adults will be treated with either sirolimus or everolimus for 6 weeks. All participants will take one capsule weekly. This dose escalation trial will begin with two cohorts, each consisting of 3 male and 3 female participants. The first two cohorts will take a weekly 5mg dose of sirolimus or a weekly 5mg dose of everolimus. The first arm of the study will be with everolimus. The second arm of the study will be with sirolimus. The dose can be escalated/de-escalated from the current dose based on the rate of dose limited toxicity (DLT) at the end of the 6-week intervention for each cohort. The 15mg dose will be the highest dose possible in this trial.

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Safer mTOR Inhibition for Human Geroprotection

Anticipated Study Start Date :

Jan 1, 2024

Anticipated Primary Completion Date :

Mar 1, 2027

Anticipated Study Completion Date :

Dec 1, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sirolimus 1mg tablets of sirolimus that total the assigned dose	Drug: Sirolimus 5mg, 10mg, or 15mg once weekly sirolimus Other Names: Rapamycin
Experimental: Everolimus 1mg tablets of everolimus that total the assigned dose	Drug: Everolimus 5mg, 10mg, or 15mg once weekly everolimus

Arm

Intervention/Treatment

Experimental: Sirolimus

1mg tablets of sirolimus that total the assigned dose

Drug: Sirolimus

5mg, 10mg, or 15mg once weekly sirolimus

Other Names:

Rapamycin

Experimental: Everolimus

1mg tablets of everolimus that total the assigned dose

Drug: Everolimus

5mg, 10mg, or 15mg once weekly everolimus

Outcome Measures

Primary Outcome Measures

Dose Limited Toxicities (DLTs) [Through study completion, an average 3 years]
A recommended phase 2 dose (RP2D) will be determined through evaluating dose limiting toxicities (DLT), which is defined as ≥Grade 2 adverse event following CTCAE v6.0.

Secondary Outcome Measures

Time course of drug concentration in blood [First dose to 168 hours post dose]
Using PK parameters of Peak Plasma Concentration (Cmax, Cmin), determine duration of concentration of drug in blood measured pre dose, and 0.5, 1.5, 4, 48, and 168 hours post dose
Time course of drug concentration in blood [First dose to 168 hours post dose]
Using PK parameters of Area under the plasma concentration versus time curve (AUC, T1/2), determine duration of concentration of drug in blood measured pre dose, and 0.5, 1.5, 4, 48, and 168 hours post dose
Change in mTOR signaling in blood and muscle [0 (pre-intervention) and 6 weeks (post-intervention)]
To be evaluated through immunoblotting and immunoprecipitation
Change in concentration of metabollites [0 (pre-intervention) and 6 weeks (post-intervention)]
Metabolomics: Change in concentration of blood and/or skeletal muscle metabolites as assessed by liquid chromatography mass spectrometry
Change in concentration of lipid species [0 (pre-intervention) and 6 weeks (post-intervention)]
Lipidomics: Change in the concentration of lipid species in blood and/or skeletal muscle as assessed by liquid chromatography mass spectrometry
Change in transcriptome [0 (pre-intervention) and 6 weeks (post-intervention)]
Change in skeletal muscle and whole blood transcripts assessed via RNA sequencing
Change in glucose tolerance [0 (pre-intervention) and 6 weeks (post-intervention)]
Assess change in glucose tolerance by area under the curve
Change in whole body insulin sensitivity [0 (pre-intervention) and 6 weeks (post-intervention)]
Insulin sensitivity as assessed by the Matsuda Index.
Change in glucose variability [0 (pre-intervention) and 6 weeks (post-intervention)]
Glucose Variability will be assessed via continuous glucose monitoring during two occasions during weeks 0, and 6 by measuring the change in range.
Change in glucose variability [0 (pre-intervention) and 6 weeks (post-intervention)]
Glucose Variability will be assessed via continuous glucose monitoring during two occasions during weeks 0, and 6 by measuring the change in total standard deviation.
Change in glucose variability [0 (pre-intervention) and 6 weeks (post-intervention)]
Glucose Variability will be assessed via continuous glucose monitoring during two occasions during weeks 0, and 6 by measuring the change in mean daily differences (MODD).
Change in glucose variability [0 (pre-intervention) and 6 weeks (post-intervention)]
Glucose Variability will be assessed via continuous glucose monitoring during two occasions during weeks 0, and 6 by measuring the change in the overall net glycemic action over a 4-h and 8-h period (CONGA4; CONGA8).
Change in insulin resistance [0 (pre-intervention) and 6 weeks (post-intervention)]
Measured by change in homeostatic model of insulin resistance (HOMA-IR).

Eligibility Criteria

Criteria

Ages Eligible for Study:

55 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Middle-age adults free of overt chronic disease
Willing to provide informed consent
Willing to comply with all study procedures and be available for the duration of the study
Able to use and be contacted by telephone
Ability to take oral medication
Not planning to change diet or physical activity status
Adequate organ function as indicated by standard laboratory tests: hematology (complete blood count), and clinical chemistry
Males must agree to avoid impregnation of women during and for four weeks after completing study visits through use of an acceptable method of contraception

Exclusion Criteria:

Heart disease (history, abnormal ECG)
Cerebrovascular disease (history)
Cancer or less than 5 years in remission (history)
Chronic respiratory disease (history, FEV1/FVC < 70, FEV1 < 80% predicted)
Chronic liver disease (history, abnormal blood liver panel, ALT >104 IU/L, AST >80 IU/L)
Diabetes (history, HbA1C ≥ 6.5, fasting blood glucose≥126 mg/dl, OGTT ≥ 200 mg/dl at 2 hrs.)
Alzheimer's (history)
Chronic kidney disease (history, abnormal blood kidney panel including serum creatinine>1.4, eGFR≤60 ml/min/1.73m2)
Problems with bleeding, on medication that prolongs bleeding time (if subject cannot safely stop prior to biopsy)
Taking azathioprine (Imuran), cyclosporine (Gengraf, Neoral, Sandimmune), dexamethasone (Decadron, Dexpak), methotrexate (Rheumatrex, Trexall), prednisolone (Orapred, Pediapred, Prelone), prednisone (Sterapred), sirolimus (Rapamune), and tacrolimus (Prograf) or other medications proposed to lower the immune system
Taking strong or moderate CYP3A4 and/or P-glycoprotein (PgP) inhibitors such as ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole, amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem
Taking strong CYP3A4 activators such as phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital
Subjects who are not willing to restrict the use of grapefruit, grapefruit juice, cannabidiol (CBD) and other foods/substances that are known to inhibit cytochrome P450 and PgP activity and may increase everolimus exposures and should be avoided during treatment
Subjects who are not willing to restrict the use of St. John's Wort (Hypericum perforatum) because it may decrease everolimus exposure unpredictably.
Subjects who are not willing to avoid blood donations 8 weeks prior to the first visit and 8 weeks after the last visit
Low white-blood cell count (<4,000 cell/µL)
History of stomatitis or ulcers in the mouth
Those on glucose lowering drugs
Participating in intensive exercise training program (high to moderate intensity exercise greater than 150 minutes per week) or planning to start new exercise program during study period
Tobacco use
Allergies to lidocaine, sirolimus, or everolimus
Subjects currently enrolled in other clinical trials. Subjects may be eligible after a washout period that will be reviewed on a case-by-case basis.
Individuals with limited English proficiency
Subjects who are planning to have elective surgery 12 weeks prior to or during the intervention